TABLE 1.
Patient (N = 156) baseline demographic and COVID-19–related data
| All Patients (N = 156) | Confirmed COVID-19 (n = 87) | Presumed COVID-19 (n = 69) | |
|---|---|---|---|
| Female | 107 (69) | 54 (62) | 53 (77) |
| Age, median (range), yr | 44 (13–79) | 45 (13–79) | 44 (14–79) |
| BMI, median (range), kg/m2 | 24 (16–52) | 24 (17–52) | 24 (16–42) |
| Race | |||
| White | 119 (76) | 65 (75) | 54 (78) |
| Asian | 8 (5) | 3 (3) | 5 (7) |
| Black or African American | 6 (4) | 4 (5) | 2 (3) |
| American Indian or American Native | 2 (1) | 1 (1) | 1 (1) |
| Native Hawaiian or Pacific Islander | 0 (0) | 0 (0) | 0 (0) |
| Other | 15 (10) | 8 (9) | 7 (10) |
| Hispanic or Latinx | 10 (7) | 3 (4) | 7 (10) |
| Duration of symptoms, median (range), d | 351 (82–457) | 350 (157–424) | 355 (82–457) |
| PCR completed | 98 (63) | 57 (66) | 41 (59) |
| PCR positive | 34 (22) | 34 (39) | 0 (0) |
| Antibody test completed | 149 (96) | 86 (99) | 63 (91) |
| Antibody positive | 80 (51) | 80 (92) | 0 (0) |
| PCR and/or antibody positive | 87 (56) | 87 (100) | 0 (0) |
| Hospitalized for COVID-19 | 17 (11) | 16 (18) | 1 (1) |
| Received COVID-19 vaccinationa | 87 (56) | 45 (52) | 42 (61) |
| Most prevalent comorbidities | |||
| Cancer (any type) | 30 (20) | 10 (11) | 20 (29) |
| Asthma | 30 (20) | 13 (15) | 17 (25) |
| Anxiety | 18 (12) | 12 (14) | 6 (9) |
| Depression | 13 (8) | 8 (9) | 5 (7) |
| Hypertension | 11 (7) | 7 (8) | 4 (6) |
Data are presented as n (%) unless otherwise indicated.
aAll COVID-19 vaccination occurred after COVID-19 infection.
BMI, body mass index.